Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/36229
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | ZELNIKER, Thomas A. | |
dc.contributor.author | BONACA, Marc P. | |
dc.contributor.author | FURTADO, Remo H. M. | |
dc.contributor.author | MOSENZON, Ofri | |
dc.contributor.author | KUDER, Julia F. | |
dc.contributor.author | MURPHY, Sabina A. | |
dc.contributor.author | BHATT, Deepak L. | |
dc.contributor.author | LEITER, Lawrence A. | |
dc.contributor.author | MCGUIRE, Darren K. | |
dc.contributor.author | WILDING, John P. H. | |
dc.contributor.author | BUDAJ, Andrzej | |
dc.contributor.author | KISS, Robert G. | |
dc.contributor.author | PADILLA, Francisco | |
dc.contributor.author | GAUSE-NILSSON, Ingrid | |
dc.contributor.author | LANGKILDE, Anna Maria | |
dc.contributor.author | RAZ, Itamar | |
dc.contributor.author | SABATINE, Marc S. | |
dc.contributor.author | WIVIOTT, Stephen D. | |
dc.date.accessioned | 2020-06-01T15:01:33Z | - |
dc.date.available | 2020-06-01T15:01:33Z | - |
dc.date.issued | 2020 | |
dc.identifier.citation | CIRCULATION, v.141, n.15, p.1227-1234, 2020 | |
dc.identifier.issn | 0009-7322 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/36229 | - |
dc.description.abstract | Background: Atrial fibrillation (AF) and atrial flutter (AFL) are associated with both diabetes mellitus and its related comorbidities, including hypertension, obesity, and heart failure (HF). SGLT2 (sodium-glucose cotransporter 2) inhibitors have been shown to lower blood pressure, reduce weight, have salutary effects on left ventricular remodeling, and reduce hospitalization for HF and cardiovascular death in patients with type 2 diabetes mellitus. We therefore investigated whether SGLT2 inhibitors could also reduce the risk of AF/AFL. Methods: DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) studied the efficacy and safety of the SGLT2 inhibitor dapagliflozin versus placebo in 17 160 patients with type 2 diabetes mellitus and either multiple risk factors for atherosclerotic cardiovascular disease (n=10 186) or known atherosclerotic cardiovascular disease (n=6974). We explored the effect of dapagliflozin on the first and total number of AF/AFL events in patients with (n=1116) and without prevalent AF/AFL using Cox and negative binomial models, respectively. AF/AFL events were identified by search of the safety database using MedDRA preferred terms (""atrial fibrillation,"" ""atrial flutter""). Results: Dapagliflozin reduced the risk of AF/AFL events by 19% (264 versus 325 events; 7.8 versus 9.6 events per 1000 patient-years; hazard ratio [HR], 0.81 [95% CI, 0.68-0.95]; P=0.009). The reduction in AF/AFL events was consistent regardless of presence or absence of a history of AF/AFL at baseline (previous AF/AFL: HR, 0.79 [95% CI, 0.58-1.09]; no AF/AFL: HR, 0.81 [95% CI, 0.67-0.98]; P for interaction 0.89). Similarly, presence of atherosclerotic cardiovascular disease (HR, 0.83 [95% CI, 0.66-1.04]) versus multiple risk factors (HR, 0.78 [95% CI, 0.62-0.99]; P for interaction 0.72) or a history of HF (HF: HR, 0.78 [95% CI, 0.55-1.11]; No HF: HR, 0.81 [95% CI, 0.68-0.97]; P for interaction 0.88) did not modify the reduction in AF/AFL events observed with dapagliflozin. Moreover, there was no effect modification by sex, history of ischemic stroke, glycated hemoglobin A(1c), body mass index, blood pressure, or estimated glomerular filtration rate (all P for interaction >0.20). Dapagliflozin also reduced the total number (first and recurrent) of AF/AFL events (337 versus 432; incidence rate ratio, 0.77 [95% CI, 0.64-0.92]; P=0.005). Conclusions: Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus. This effect was consistent regardless of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF. Registration: URL: ; Unique identifier: NCT01730534. | eng |
dc.description.sponsorship | AstraZenecaAstraZeneca | |
dc.description.sponsorship | Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [ZE 1109/1-1] | |
dc.description.sponsorship | Lemann Foundation Cardiovascular Research Postdoctoral Fellowship -Harvard University/Brigham and Women's Hospital | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | eng |
dc.relation.ispartof | Circulation | |
dc.rights | restrictedAccess | eng |
dc.subject | atrial fibrillation | eng |
dc.subject | atrial flutter | eng |
dc.subject | diabetes mellitus | eng |
dc.subject | gliflozins | eng |
dc.subject | SGLT-2 inhibitors | eng |
dc.subject.other | cotransporter 2 inhibitors | eng |
dc.subject.other | risk | eng |
dc.subject.other | pioglitazone | eng |
dc.subject.other | metaanalysis | eng |
dc.subject.other | mechanism | eng |
dc.subject.other | events | eng |
dc.title | Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial | eng |
dc.type | article | eng |
dc.rights.holder | Copyright LIPPINCOTT WILLIAMS & WILKINS | eng |
dc.identifier.doi | 10.1161/CIRCULATIONAHA.119.044183 | |
dc.identifier.pmid | 31983236 | |
dc.subject.wos | Cardiac & Cardiovascular Systems | eng |
dc.subject.wos | Peripheral Vascular Disease | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | ZELNIKER, Thomas A.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA; Vienna Gen Hosp, Div Cardiol, Vienna, Austria; Med Univ Vienna, Vienna, Austria | |
hcfmusp.author.external | BONACA, Marc P.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA; Univ Colorado, Sch Med, Dept Med, Div Cardiol, Aurora, CO USA; CPC Clin Res, Aurora, CO USA | |
hcfmusp.author.external | MOSENZON, Ofri:Hebrew Univ Jerusalem, Dept Endocrinol & Metab, Diabet Unit, Hadassah Med Ctr, Jerusalem, Israel | |
hcfmusp.author.external | KUDER, Julia F.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA | |
hcfmusp.author.external | MURPHY, Sabina A.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA | |
hcfmusp.author.external | BHATT, Deepak L.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA | |
hcfmusp.author.external | LEITER, Lawrence A.:Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada | |
hcfmusp.author.external | MCGUIRE, Darren K.:Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA | |
hcfmusp.author.external | WILDING, John P. H.:Univ Liverpool, Inst Ageing & Chron Dis, Liverpool, Merseyside, England | |
hcfmusp.author.external | BUDAJ, Andrzej:Grochowski Hosp, Dept Cardiol, Ctr Postgrad Med Educ, Warsaw, Poland | |
hcfmusp.author.external | KISS, Robert G.:Mil Hosp, Dept Cardiol, Budapest, Hungary | |
hcfmusp.author.external | PADILLA, Francisco:Cardiol Clin & Intervencionista Tarascos, Guadalajara, Jalisco, Mexico | |
hcfmusp.author.external | GAUSE-NILSSON, Ingrid:AstraZeneca Gothenburg, Molndal, Sweden | |
hcfmusp.author.external | LANGKILDE, Anna Maria:AstraZeneca Gothenburg, Molndal, Sweden | |
hcfmusp.author.external | RAZ, Itamar:Hebrew Univ Jerusalem, Dept Endocrinol & Metab, Diabet Unit, Hadassah Med Ctr, Jerusalem, Israel | |
hcfmusp.author.external | SABATINE, Marc S.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA | |
hcfmusp.author.external | WIVIOTT, Stephen D.:Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA | |
hcfmusp.description.beginpage | 1227 | |
hcfmusp.description.endpage | 1234 | |
hcfmusp.description.issue | 15 | |
hcfmusp.description.volume | 141 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000528600200007 | |
hcfmusp.origem.id | 2-s2.0-85083675930 | |
hcfmusp.publisher.city | PHILADELPHIA | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9 | eng |
hcfmusp.relation.reference | Fangel MV, 2019, CIRC-ARRHYTHMIA ELEC, V12, DOI 10.1161/CIRCEP.118.007030 | eng |
hcfmusp.relation.reference | Gu J, 2013, J MOL CELL CARDIOL, V65, P1, DOI 10.1016/j.yjmcc.2013.09.016 | eng |
hcfmusp.relation.reference | Hatem SN, 2014, CARDIOVASC RES, V102, P205, DOI 10.1093/cvr/cvu045 | eng |
hcfmusp.relation.reference | Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3 | eng |
hcfmusp.relation.reference | Huxley RR, 2011, AM J CARDIOL, V108, P56, DOI 10.1016/j.amjcard.2011.03.004 | eng |
hcfmusp.relation.reference | January CT, 2019, CIRCULATION, V140, pE125, DOI 10.1161/CIR.0000000000000665 | eng |
hcfmusp.relation.reference | KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703 | eng |
hcfmusp.relation.reference | Kidokoro K, 2019, CIRCULATION, V140, P303, DOI 10.1161/CIRCULATIONAHA.118.037418 | eng |
hcfmusp.relation.reference | Ko SH, 2018, J DIABETES COMPLICAT, V32, P157, DOI 10.1016/j.jdiacomp.2017.09.009 | eng |
hcfmusp.relation.reference | Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9 | eng |
hcfmusp.relation.reference | Liu B, 2014, INT HEART J, V55, P499, DOI 10.1536/ihj.14-107 | eng |
hcfmusp.relation.reference | Liu CL, 2017, CARDIOVASC THER, V35, DOI 10.1111/1755-5922.12284 | eng |
hcfmusp.relation.reference | McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303 | eng |
hcfmusp.relation.reference | Monami M, 2017, J ENDOCRINOL INVEST, V40, P1251, DOI 10.1007/s40618-017-0698-7 | eng |
hcfmusp.relation.reference | Packer M, 2019, CIRCULATION, V140, P443, DOI 10.1161/CIRCULATIONAHA.119.040909 | eng |
hcfmusp.relation.reference | Perkovic V, 2019, NEW ENGL J MED, V380, P2295, DOI 10.1056/NEJMoa1811744 | eng |
hcfmusp.relation.reference | Plitt A, 2017, JAMA CARDIOL, V2, P442, DOI 10.1001/jamacardio.2016.5224 | eng |
hcfmusp.relation.reference | Raz I, 2018, DIABETES OBES METAB, V20, P1102, DOI 10.1111/dom.13217 | eng |
hcfmusp.relation.reference | Saito S, 2014, CARDIOVASC RES, V104, P5, DOI 10.1093/cvr/cvu176 | eng |
hcfmusp.relation.reference | Sano M, 2019, CIRCULATION, V139, P1985, DOI 10.1161/CIRCULATIONAHA.118.038881 | eng |
hcfmusp.relation.reference | Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9 | eng |
hcfmusp.relation.reference | Sato T, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-017-0658-8 | eng |
hcfmusp.relation.reference | SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.2307/2335876 | eng |
hcfmusp.relation.reference | Uthman L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01575 | eng |
hcfmusp.relation.reference | Verma S, 2019, CIRCULATION, V140, P1693, DOI 10.1161/CIRCULATIONAHA.119.042375 | eng |
hcfmusp.relation.reference | Wang A, 2019, J AM COLL CARDIOL, V74, P1107, DOI 10.1016/j.jacc.2019.07.020 | eng |
hcfmusp.relation.reference | Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389 | eng |
hcfmusp.relation.reference | Wiviott SD, 2018, AM HEART J, V200, P83, DOI 10.1016/j.ahj.2018.01.012 | eng |
hcfmusp.relation.reference | Yurista SR, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-019-0984-0 | eng |
hcfmusp.relation.reference | Zelniker Thomas A, 2019, Card Fail Rev, V5, P27, DOI 10.15420/cfr.2018.44.1 | eng |
hcfmusp.relation.reference | Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X | eng |
hcfmusp.relation.reference | Zelniker TA, 2018, J AM COLL CARDIOL, V72, P1845, DOI 10.1016/j.jacc.2018.06.040 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1524-4539 | |
hcfmusp.citation.scopus | 230 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_ZELNIKER_Effect_of_Dapagliflozin_on_Atrial_Fibrillation_in_Patients_2020.PDF.pdf Restricted Access | publishedVersion (English) | 535.74 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.